Tag: Biocon Biologics Ltd.

3 results found

Mylan has completely exited Biocon Ltd by selling its entire 5.64% stake for ₹3,679 crore in a massive pre-open block deal on July 14, 2026

261views

0likes

0comments

Market
Corporate

Mylan sells its 5.64% Biocon stake within six months, institutional...

Mumbai: US-based generic pharma major Mylan has sold its 5.64% share in Biocon Ltd within 6 months of getting it. The shares were allocated to it as part of an...

By Abizar Attari
July 15, 2026

Biocon Biologics has published Phase III clinical data in top peer-reviewed journals proving that its FDA-approved drug Yesafili is fully interchangeable with the eye medication Eylea

252views

0likes

0comments

Business
Corporate

Biocon Biologics gets a step closer to launching its Aflibercept...

Bengaluru: Biocon Biologics Limited is now a step closer to launching its Aflibercept biosimilar, after gaining approval from the US FDA under the name Yesafili in May 2024. It has...

By Abizar Attari
July 9, 2026

466views

0likes

0comments

Corporate

Biocon registers Rs 3,516 cr revenues in Q1FY24, Up 59%

New Delhi: Biocon, an Indian pharmaceuticals giant, registered Rs 3,516 crore in revenues for Quarter 1 of FY 2024. An official statement issued by the company said that the profits were...